NAYA Biosciences Bolsters Board with Industry Veterans

NAYA Biosciences (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, has announced the nomination of five new board members with extensive experience in the biotechnology industry. These appointments reflect the company's enhanced focus on oncology and autoimmune diseases and aim to strengthen its strategic direction and growth prospects.

The new board members, to be approved at the company's shareholder meeting on March 10th, 2025, bring a wealth of expertise in R&D, business development, and investment management. Here's a closer look at each nominee and their potential impact on NAYA Biosciences:

1. Laurent Audoly, PhD: As the cofounder and CEO of PriveBio, a precision medicine company, and a former founding president and CEO of Kymera Therapeutics, Dr. Audoly brings a strong track record in biotech leadership and R&D. His background in pharmacology and drug development, along with his experience in scaling biotechs across multiple therapeutic areas, can help NAYA optimize its drug development pipeline and expand its reach in oncology and autoimmune diseases. Dr. Audoly's involvement in eight drug approvals during his tenure at Pierre Fabre Group also demonstrates his ability to navigate the regulatory landscape, which is crucial for bringing new treatments to market.
2. Melissa Fensterstock, MPhil, MBA: Ms. Fensterstock's experience as an advisor with Material Impact Fund, CEO and board member of Lansdowne Labs, and executive-in-residence at various universities brings a unique perspective to NAYA Biosciences' board. Her background in translating innovations from academic settings to commercial scale can help the company identify and capitalize on promising early-stage assets in oncology and autoimmune diseases. Ms. Fensterstock's education in neuroscience, bioscience enterprise, and business administration also equips her to make strategic decisions that balance scientific innovation with commercial viability.
3. Prakash Raman, PhD: Dr. Raman's extensive experience in business development and licensing at Novartis, along with his current roles as CEO of InduPro and director at Black Diamond Therapeutics, makes him an invaluable addition to NAYA Biosciences' board. His expertise in forging key collaborations, executing out-licensing opportunities, and guiding acquisitions can help NAYA strategically partner with other companies and academia to advance its pipeline. Dr. Raman's background in organic and medicinal chemistry also provides a scientific foundation for evaluating potential assets and technologies.
4. Daniel Teper, PharmD, MBA: As the founder and president of NAYA Biosciences, Dr. Teper's leadership and experience in the biotechnology industry are well-established. His background in pharmacy, business, and senior management positions at various companies enables him to make informed decisions about the company's strategic direction. Dr. Teper's involvement in leading Immune Pharmaceuticals to its NASDAQ listing demonstrates his ability to navigate the competitive biotech landscape and create value for shareholders.
5. Alexandra Urman, MPH: Ms. Urman's experience as an analyst and portfolio manager at the intersection of biotechnology and healthcare innovation, along with her roles as CEO of Aomics and senior vice president of the Florida-Israel Business Accelerator's Venture Fund, brings a unique investment perspective to NAYA Biosciences' board. Her background in clinical cancer research, AI integration in healthcare, and portfolio management can help the company make strategic investments in promising technologies and assets, as well as evaluate the potential of its existing pipeline.



In conclusion, the nomination of these five new board members with diverse expertise in R&D, business development, and investment management can significantly contribute to NAYA Biosciences' long-term growth and success in the competitive biotechnology landscape. Their collective experience in the industry can help NAYA advance its pipeline, forge strategic partnerships, and make informed investment decisions, ultimately strengthening its position in the market. As NAYA continues to focus on oncology, autoimmune diseases, and women's health, these new board members can play a crucial role in guiding the company's strategic direction and driving its long-term success.